Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
CAMBRIDGE, Mass., Sept. 21, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Ladenburg Thalmann 2016 Healthcare Conference at Sofitel Hotel in New York City, NY on Tuesday, September 27, 2016, at 11:30am Eastern time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: http://wsw.com/webcast/ladenburg2/vcel.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel‑T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel® and MACI® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
